No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 11
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T22:04:26.991Z. Latest historical point 2026-10-05.
The latest delayed quote for Translational Development Acquisition Corp. (TDAC) stock was $10.82 as of Oct 6, 2026, 4:00 PM EDT, down 0.05% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +4.7%
Translational Development Acquisition Corp., founded in 2022 and headquartered in New York, New York, currently conducts no significant business operations. Its primary goal is to complete a business combination, such as a merger, amalgamation, share exchange, asset acquisition, share purchase, or reorganization, with one or more companies.
Shell Companies · New York City, NY
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$0.04
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TDAC | $266.50M | $10.82 | -0.05% | +4.72% | N/A | N/A | N/A |
| 2TBCVU | $266.29M | $9.92 | -0.01% | N/A | N/A | N/A | vs TDAC |
| 3HWBK | $265.95M | $38.54 | +0.50% | +29.06% | +15.43% | +16.23% | vs TDAC |
| 4KINS | $267.82M | $18.49 | -0.32% | +24.75% | +24.49% | +8.81% | vs TDAC |
| 5LCNB | $268.25M | $18.83 | -0.48% | +32.66% | +7.06% | +5.14% | vs TDAC |
| 6OACC | $264.51M | $10.76 | +0.00% | +1.98% | N/A | N/A | vs TDAC |
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$10.82
High
N/A
